ArticleHealth science reports2026
The Burden of Urticaria in the Middle East and North Africa Region From 1990 to 2021: A Systematic Analysis Based on the GBD Study 2021.
Article in Health science reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background and Aims: Urticaria is a condition which can impair the quality of life of affected individuals. There is a lack of recent studies on the burden of this disease in the Middle East and North Africa (MENA) region. This article reported the incidence, prevalence, and disability-adjusted life years (DALYs) of urticaria from 1990 to 2021 in the MENA region, by age, sex, and socio-demographic index (SDI). Methods: We retrieved data from the Global Burden of Disease (GBD) study 2021 on the incidence, prevalence, and DALYs due to urticaria in the MENA region. They were estimated using the DisMod-MR 2.1 tool. The values were presented as total counts and age-standardized rates per 100,000 individuals alongside their 95% uncertainty intervals (UIs). Results: In 2021, the age-standardized incidence rate was 1649.2 (95% UI: 1452.7-1854.3), the point prevalence was 936.1 (95% UI: 825.8-1058.6) and the DALY rate was 56.1 (95% UI: 36.8-79.2) per 100,000 in MENA region, with no significant changes since 1990. Egypt displayed the highest burden of urticaria, while Turkey had the lowest one. The incident cases and rates were highest in younger ages with the peak observed in children under-5 years old with higher incidence in women across all ages. Countries with mid-level SDI had the highest age-standardized DALY rates. Conclusion: Overall, the burden of urticaria has not changed significantly since 1990. Studies on standardizing reporting to strengthen future burden estimates, raising awareness and improving access to healthcare resources and lastly reducing exposure to environmental factors such as pollutants and allergens are recommended.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.